Loading...
Bruton tyrosine kinase inhibitor ONO/GS-4059: from bench to bedside
The Bruton tyrosine kinase (BTK) inhibitor, ibrutinib, has been approved for the treatment of chronic lymphocytic leukemia, mantle cell lymphoma, and Waldenstroms macroglobulinemia. Acquired resistance to ibrutinib due to BTK C481S mutation has been reported. Mutations in PLC?2 can also mediate resi...
Saved in:
| Published in: | Oncotarget |
|---|---|
| Main Authors: | , , |
| Format: | Artigo |
| Language: | Inglês |
| Published: |
Impact Journals LLC
2016
|
| Subjects: | |
| Online Access: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5351700/ https://ncbi.nlm.nih.gov/pubmed/27776353 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.12786 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|